Literature DB >> 1832133

Pelvic abscesses: pelviscopy or laparotomy.

H Mecke1, K Semm, I Freys, H J Gent.   

Abstract

Between 1983 and 1988, we treated 66 patients with pelvic abscesses. Twenty-five patients required laparotomy and 41 underwent pelviscopy for treatment. The choice of the operative procedure, laparotomy or pelviscopy, depended on the age of the patient, the clinical presentation and the operative findings. The two collectives demonstrated no differences in the duration of hospitalization and in-patient treatment with antibiotics. A conservative, organ-preserving procedure could be performed in 80% of patients operated pelviscopically. In follow-up examinations 1-2 years after operation, 27% of the patients treated per pelviscopy complained of chronic abdominal pain as compared to 37% of those treated per laparotomy. In young patients, pelviscopic treatment of pelvic abscesses is a valuable alternative to laparotomy.

Entities:  

Keywords:  Adnexal Effects; Antibiotics; Biology; Comparative Studies; Contraception; Contraceptive Methods; Culdoscopy; Developed Countries; Diseases; Drugs; Endoscopy; Europe; Examinations And Diagnoses; Family Planning; Genital Effects, Female; Genitalia; Genitalia, Female; Germany, Federal Republic Of; Gynecologic Surgery; Hysterectomy; Infections; Iud; Laparotomy; Methodological Studies; Ovariectomy; Pain; Pelvic Infections; Physical Examinations And Diagnoses; Physiology; Research Methodology; Signs And Symptoms; Studies; Surgery; Treatment; Urogenital Surgery; Urogenital System; Western Europe

Mesh:

Substances:

Year:  1991        PMID: 1832133     DOI: 10.1159/000293165

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  1 in total

1.  Laparoscopic management of tubo-ovarian abscesses: retrospective analysis of 60 cases.

Authors:  O Buchweitz; E Malik; P Kressin; A Meyhoefer-Malik; K Diedrich
Journal:  Surg Endosc       Date:  2000-10       Impact factor: 4.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.